NanoTess Deploys Catalytic Wound Care Technology to Ukrainian Front Lines
Calgary-based biotech startup provides advanced topical gel treatments to soldiers and civilians in conflict.
1Biotech Innovation in Conflict
Calgary-based startup NanoTess has deployed its flagship product, NanoSALV Catalytic, to treat soldiers and civilians in Ukraine. The topical gel utilizes specialized catalytic particles designed to accelerate the healing process for complex injuries. This medical intervention has already reached over 6,000 individuals impacted by the ongoing war in the region.
2Addressing Combat-Related Trauma
Military surgeon Dr. Vasyl Voronets highlights that burns and complex blast wounds, often caused by drone strikes, are highly susceptible to debris contamination and rapid infection. In active conflict zones where medical access is severely restricted, the application of this gel provides a critical layer of defense against complications for frontline personnel.
3Logistics and Strategic Partnerships
To navigate the dangerous and remote terrain of the Ukrainian front lines, NanoTess relies on a collaborative supply chain. The company partners with Medical Mercy Canada, the Public Health Centre of Ukraine, and the Medical Forces Sustainment Group East. Much of the actual delivery to these high-risk areas is facilitated via drone technology.
4Regulatory and Commercial Scale
Since receiving authorization from Health Canada in 2022, the product has achieved significant market penetration. NanoSALV is currently utilized in over 2,500 hospitals and health facilities across the country. Furthermore, the product is accessible to the public through a network of 14,000 pharmacies, demonstrating its established efficacy and widespread clinical adoption.
5Institutional Support and Growth
In 2023, NanoTess gained momentum through support from the CAN Health Network, a federally funded organization focused on commercializing health-tech solutions. This partnership helped bridge the gap between private sector innovation and healthcare providers. Such institutional backing has been instrumental in scaling the company’s operations and expanding its reach into international markets.
6Dual-Use Technology Strategy
NanoTess has actively pivoted toward dual-use capabilities, aligning its business model with national security interests. The company participates in the Department of National Defence’s Innovation for Defence Excellence and Security program. This initiative provides the necessary support to build out manufacturing capacity, ensuring the technology can serve both civilian and military needs.
7Strengthening Canada-Ukraine Relations
The deployment occurs within a broader framework of deepened cooperation between Canada and Ukraine. In September, a 100-year declaration on defense innovation was signed by national leaders. This diplomatic alignment prioritizes the integration of private sector dual-use technologies, positioning companies like NanoTess as vital contributors to the broader defense and humanitarian expansion.
8Impact of Specialized Medical Aid
The successful integration of NanoSALV into Ukraine’s medical response demonstrates the importance of agile biotech solutions in modern warfare. By focusing on infection prevention and rapid healing, the technology addresses specific tactical medical challenges. This case underscores how private sector innovation can directly influence outcomes in high-stakes, resource-constrained environments globally.